Antibodies need to possess a multitude of properties to be manufacturable, safe, and efficacious for patients. This is a hard engineering problem with a high a failure rate, because today’s discovery technologies rely on brute-force guess-and-check. At Nabla, we're building a protein design platform that enables us to build antibodies deliberately, with all the properties they need to reach and treat patients, and do so faster than we can today.

Learn more at: https://www.nabla.bio/